Q3 2023 BioArctic AB Earnings Call Transcript
This call is being recorded. Welcome to the BioArctic Q3 presentation for 2023. (Operator Instructions) Now I will hand the conference over to the CEO, Gunilla Osswald; and CFO, Anders Martin-Lof. Please go ahead.
()-
Good morning, and welcome to BioArctic's presentation for the third quarter of 2023. I'm Gunilla Osswald and I'm the CEO of BioArctic and I will share today's presentation with our CFO, Anders Martin-Lof. I think it's very exciting times for BioArctic with LEQEMBI being the first and only disease-modifying treatment with a full approval in the U.S. and now also in Japan. And both these things happened during this quarter. I think it's beginning of a new era. And BioArctic is behind this true breakthrough in the treatment of Alzheimer's disease. I find this extremely gratifying that we now can help a large number of patients and families around the world. And I'll talk more about that here today.
Next slide, please. BioArctic is listed at Nasdaq Stockholm Large Cap and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |